Salarius Pharmaceuticals Points Out Mistakes on S&P CapIQ Platform After Merging with Decoy Therapeutics, Confirms Its Shares Remain Listed on Nasdaq Under the Symbol "SLRX"
Correction of Misinformation: Salarius Pharmaceuticals addresses an error on the S&P CapIQ platform that incorrectly stated the company had been delisted from Nasdaq, confirming that its stock continues to trade under the ticker "SLRX."
Recent Financial Activities: The company completed an $8 million public offering and merged with Decoy Therapeutics, resulting in a combined cash position of approximately $14 million and around 5.9 million shares outstanding.
Focus on Drug Development: Salarius is advancing Decoy's pipeline of peptide conjugate therapeutics, utilizing its IMP3ACT platform, which incorporates AI and machine learning to streamline drug development.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SLRX
About SLRX
About the author

GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.

Salarius Pharmaceuticals Adjourns Annual Meeting to December 31 Due to Insufficient Votes
- Annual Meeting Postponed: Salarius Pharmaceuticals' Annual Meeting scheduled for December 19, 2025, was adjourned due to insufficient quorum, as less than 34% of outstanding shares were represented, indicating low shareholder engagement that could affect decision-making efficacy.
- Insufficient Voting Power: At the time of adjournment, only approximately 30% of shares had been voted, failing to meet the legal requirement, which may delay critical company decisions and impact future strategic direction.
- Rescheduled Meeting: The meeting will reconvene on December 31, 2025, at 10:00 a.m. Central Time via live webcast, with shareholders encouraged to vote promptly, aiming to ensure transparency in governance and active shareholder participation.
- Importance of Shareholder Voting: The company underscores the significance of shareholder votes, urging eligible stockholders as of the October 24, 2025 record date to vote online or by phone, ensuring their voices are heard in corporate decision-making.









